Mylan Tapped for More Information on EpiPen Price Figures

A U.S. House committee sent a letter to Mylan demanding a fuller explanation of why the company omitted key information that it used to calculate the profit figure for the lifesaving EpiPen drug that its chief executive provided during a congressional hearing last month.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news